AMPA Receptor Antagonists: Potential Therapeutic Applications

Authors: Mattes, Henri; Lingenhoehl, Kurt; Kalkman, Hans; Auberson, Yves; Renaud, Johanne; Schmutz, Markus; Orain, David

Source: Recent Patents on CNS Drug Discovery, Volume 1, Number 3, November 2006 , pp. 247-259(13)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $113.00 plus tax (Refund Policy)

Abstract:

The current review will focus on the recent patents for AMPA receptor antagonists and their claims, evidence for their therapeutic effectiveness in the treatment of epilepsy and their potential role in psychiatric and neurodegenerative disorders. It will also highlight the proposed mechanisms of action and the implications thereof for our current understanding of the biomolecular basis of these pathologies. It will conclude with a summary of what we know, but also point out the remaining uncertainties, especially as this relates to the claims in the patent under discussion.

Keywords: AMPA; glutamate; antagonist; epilepsy; schizophrenia; ALS; multiple sclerosis; neuroprotection; anxiety; antiproliferative

Document Type: Research article

DOI: http://dx.doi.org/10.2174/157488906778773698

Affiliations: 1: Novartis Institute for Biomedical Research, Novartis Pharma AG, Lichtstrasse 35, CH-4056 Basel, Switzerland.

Publication date: 2006-11-01

More about this publication?

Recent Patents on CNS Drug Discovery publishes review articles on recent patents in the field of CNS drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on CNS drug discovery is also included in the journal. The journal is essential reading for all researchers involved in CNS drug design and discovery.